Drug intelligence / Profile preview

lamotrigine

Development stage: Approved
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

Lamotrigine is an antiepileptic drug used to treat epilepsy and bipolar disorder. It works by calming overactive nerves in the body, primarily through the inhibition of excitatory neurotransmitter release via voltage-sensitive sodium channels and voltage-gated calcium channels in neurons. It is used to control seizures in epilepsy and to stabilize mood in bipolar disorder, preventing episodes of depression and mania.

Brand names: LamictalLamictal XRLamictal ODTLamictal CDSubvenite
Other names: lamotrigineLamictalGI267119GI-267119GI 267119

Targets

CACNA1E (Voltage-dependent R-type calcium channel subunit alpha-1E)NaV (Voltage-gated sodium channels)VDCC (L-type voltage-dependent calcium channel (often specified further as subunits such as CaV1.2 in humans))

Beyond the preview

Go deeper on lamotrigine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lamotrigine.

Explore the full profile